The estimated Net Worth of Susan H Alexander is at least $24.3 Milion dollars as of 16 February 2024. Ms. Alexander owns over 5,037 units of Biogen Inc stock worth over $10,445,058 and over the last 19 years she sold BIIB stock worth over $8,358,891. In addition, she makes $5,455,010 as Executive Vice President i Chief Legal Officer and Secretary at Biogen Inc.
Susan has made over 46 trades of the Biogen Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently she exercised 5,037 units of BIIB stock worth $1,002,816 on 16 February 2024.
The largest trade she's ever made was exercising 58,070 units of Biogen Inc stock on 27 July 2012 worth over $3,312,313. On average, Susan trades about 3,682 units every 74 days since 2006. As of 16 February 2024 she still owns at least 52,464 units of Biogen Inc stock.
You can see the complete history of Ms. Alexander stock trades at the bottom of the page.
Susan H. Alexander, Esq., is Executive Vice President, Chief Legal Officer and Secretary of the Company. Prior to that, from March 2017 to March 2018, Ms. Alexander served as our Executive Vice President, Chief Legal, Corporate Services and Secretary, from December 2011 to March 2017, as our Executive Vice President, Chief Legal Officer and Secretary and from 2006 to December 2011, as our Executive Vice President, General Counsel and Corporate Secretary. Prior to joining Biogen, Ms. Alexander served as the Senior Vice President, General Counsel and Corporate Secretary of PAREXEL International Corporation, a biopharmaceutical services company, from 2003 to January 2006. From 2001 to 2003 Ms. Alexander served as General Counsel of IONA Technologies, a software company. From 1995 to 2001 Ms. Alexander served as Counsel at Cabot Corporation, a specialty chemicals and performance materials company. Prior to that, Ms. Alexander was a partner at the law firms of Hinckley, Allen & Snyder and Fine & Ambrogne.
As the Executive Vice President i Chief Legal Officer and Secretary of Biogen Inc, the total compensation of Susan Alexander at Biogen Inc is $5,455,010. There are 1 executives at Biogen Inc getting paid more, with Michel Vounatsos having the highest compensation of $18,159,900.
Susan Alexander is 63, she's been the Executive Vice President i Chief Legal Officer and Secretary of Biogen Inc since 2018. There are 7 older and 16 younger executives at Biogen Inc. The oldest executive at Biogen Inc is Stelios Papadopoulos, 72, who is the Independent Chairman of the Board.
Susan's mailing address filed with the SEC is BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE, MA, 02142.
Over the last 21 years, insiders at Biogen Inc have traded over $166,883,156 worth of Biogen Inc stock and bought 665,319 units worth $183,001,783 . The most active insiders traders include Adam Koppel, Alexander J Denner oraz Stelios Papadopoulos. On average, Biogen Inc executives and independent directors trade stock every 10 days with the average trade being worth of $2,343,090. The most recent stock trade was executed by Priya Singhal on 30 August 2024, trading 1,668 units of BIIB stock currently worth $332,082.
through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili
Biogen Inc executives and other stock owners filed with the SEC include: